Clearance would enable system integration with a continuous glucose monitor (CGM) sensor based on Abbott’s most advanced platform. This marks the latest development in a landmark collaboration between the two medtech giants.
Last summer, the companies announced a global partnership pairing Abbott CGMs with Medtronic insulin delivery systems. The partnership aims to collaborate on a system based on Abbott’s FreeStyle Libre CGMs with Medtronic’s automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.
Medtronic’s systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Separate from the collaboration, Medtronic just last week earned FDA approval for its own Simplera Sync CGM with MiniMed 780G.
Medtronic said its submissions included an application for MiniMed 780G as an alternate controller-enabled (ACE) insulin pump. A separate 510(k) submission covered the company’s SmartGuard algorithm as an interoperable automated glycemic controller (iAGC).
Under the companies’ agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM. They plan to share more details following the expected FDA clearance.
“We understand how meaningful these advancements are, and we’re working with urgency to bring enhanced CGM options to our customers,” said Que Dallara, EVP & president, Medtronic Diabetes. “This collaboration with Abbott marks an important step forward in providing innovative solutions and more choice for our customers.”
